^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:IBI-345 (CLDN18.2-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    ESMO 2023
    Title:

    1054P - A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors

    Published date:
    10/16/2023
    Excerpt:
    1 EGJC pt achieved PR and 2 pts (1 GC, 1 PC) achieved SD….IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors.
    Trial ID:
    NCT05199519